Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2011-10-31 Regulatory Filings
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
STADA: STADA sales companies very successful in tenders for discount agreements with various German public health insurance organizations
Regulatory Filings Classification · 99% confidence The document is a short corporate news release dated October 31, 2011, detailing the success of STADA's sales companies in securing discount agreements with German public health insurance organizations. It announces a business development outcome rather than releasing periodic financial results (ER/IR), reporting insider trades (DIRS), or announcing a meeting (AGM-R/DEF 14A). Since it is a specific, non-standard corporate announcement disseminated via a service like DGAP (which often handles regulatory news), and it doesn't fit into the more specific categories like M&A (TAR), Capital Change (CAP/SHA), or Dividend (DIV), it best fits the general regulatory announcement category, RNS, which serves as a fallback for miscellaneous corporate news releases.
2011-10-31 English
DGAP-DD: STADA Arzneimittel AG deutsch
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "Directors’ Dealings" and the German equivalent "Directors’-Dealings-Mitteilung". It details a transaction (Kauf/Buy) by a member of the supervisory board (Funktion: Verwaltungs- oder Aufsichtsorgan) involving company shares (Finanzinstruments: Aktie) on a specific date. This directly corresponds to the definition of Director's Dealing.
2011-10-06 German
DGAP-DD: STADA Arzneimittel AG deutsch
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "Directors’ Dealings" and the German equivalent "Directors’-Dealings-Mitteilung". It details a transaction (Kauf/Buy) by a member of the management board (Hartmut Retzlaff, Funktion: Geschäftsführendes Organ) involving company shares (STADA Arzneimittel AG). This directly corresponds to the definition of Director's Dealing reports.
2011-09-23 German
DGAP-DD: STADA Arzneimittel AG deutsch
Director's Dealing Classification · 100% confidence The document text explicitly contains the header "Directors’ Dealings" and the German equivalent "Directors’-Dealings-Mitteilung". It details a transaction (Kauf/Buy) by a member of the management ('Funktion: Geschäftsführendes Organ') involving company shares, including the date, price, and quantity. This directly corresponds to the definition of Director's Dealing.
2011-09-23 German
STADA: Increased risk of default on outstanding receivables from Serbian pharmaceutical wholesalers leads to burdening one-time special effects of approx. EUR 97 million before taxes
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as an "Ad-hoc" announcement disseminated according to § 15 WpHG (German Securities Trading Act). It details a significant, non-routine financial event: a large impairment charge (EUR 97 million) due to increased risk of default on receivables in Serbia. This type of immediate, material disclosure that is not a scheduled periodic report (like 10-K or IR) or a standard earnings release (ER) fits best under the general category for immediate regulatory disclosures. Since it is not a specific announcement like a dividend (DIV), management change (MANG), or capital action (CAP), and it is a direct regulatory disclosure via DGAP, the most appropriate classification is Regulatory Filings (RNS), which serves as the fallback for miscellaneous, immediate regulatory news.
2011-09-21 English
STADA Arzneimittel AG: STADA and Richter cooperate for development of two biosimilar products for two monoclonal antibodies: Rituximab and Trastuzumab
Regulatory Filings Classification · 95% confidence The document is a 'Corporate News' announcement dated August 30, 2011, detailing a license and collaboration agreement between STADA Arzneimittel AG and Gedeon Richter Plc. regarding the development and marketing of two biosimilar products (Rituximab and Trastuzumab). This announcement concerns strategic business alliances, licensing, and future product distribution rights, which falls under corporate strategic updates rather than a standard financial report (like 10-K or IR) or a specific regulatory filing like insider trading (DIRS) or dividend announcement (DIV). It is not an Earnings Release (ER) as it discusses development agreements, not period results. It is not a Call Transcript (CT) or Investor Presentation (IP). It is a specific corporate action announcement. Given the options, this type of strategic partnership announcement, which is often disseminated via regulatory news services but is fundamentally about corporate strategy and alliances, is best categorized as a general Regulatory Filing (RNS) if a more specific category like 'M&A Activity' (TAR) doesn't fit (which it doesn't, as it's a collaboration, not a takeover). However, since it details a significant business alliance and cooperation, and is disseminated as a 'Corporate News' item via DGAP, it functions as a general regulatory disclosure. Since there is no specific 'Alliance' or 'Partnership' code, RNS serves as the most appropriate general regulatory disclosure category for non-standard, material corporate news.
2011-08-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.